VistaGen Therapeutics Inc (VTGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.01M
Last updated: Nov 17, 2026 at 11:04 AM ET
VistaGen Therapeutics Inc (VTGN) Stock Forecast
Analysts expect VistaGen Therapeutics (VTGN) to earn -$1.48 per share in the fiscal year ending Mar 31, 2027, on revenue of $1.70M. Of 4 analysts, 0 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. All 4 rate it Hold.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 0 | 0.0% |
| Hold | 4 | 100.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Mar 31, 2027
- -$1.48
- EPS consensus, revenue $1.70M
- Fiscal year ending Mar 31, 2028
- -$1.54
- EPS consensus
- Next report
- Feb 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Mar 31, 2027 | -$1.48 | -$1.50 to -$1.45 | 2 | $1.70M | $1.50M to $1.90M | 2 |
| Mar 31, 2028 | -$1.54 | -$1.54 to -$1.54 | 1 | N/A | N/A | 1 |
Quarterly Estimates
The EPS consensus is -$0.37 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.37 | -$0.37 to -$0.36 | 2 | $250000 | N/A | 2 |
| Mar 31, 2027 | -$0.37 | N/A | 4 | $255000 | N/A | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Mar 31, 2027 | 0 | 2 |
| Fiscal year ending Mar 31, 2028 | 0 | 1 |
| Quarter ending Dec 31, 2026 | 0 | 2 |
EPS Trend
The EPS consensus for the fiscal year ending Mar 31, 2027 is where it was 90 days ago.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Mar 31, 2027 | -$1.48 | -$1.45 | -$1.45 | -$1.48 | -$1.48 | N/A |
| Fiscal year ending Mar 31, 2028 | -$1.54 | -$1.54 | -$1.54 | -$1.54 | -$1.11 | N/A |
| Quarter ending Dec 31, 2026 | -$0.37 | -$0.36 | -$0.36 | -$0.37 | -$0.37 | N/A |
Frequently Asked Questions About VTGN
What is the VTGN stock forecast?
Consensus analyst estimates put VistaGen Therapeutics's EPS at -$1.48 for the fiscal year ending Mar 31, 2027, on revenue of $1.70M. The consensus rating from 4 analysts is Hold.
How do analysts rate VTGN stock?
Of 4 analysts covering VistaGen Therapeutics, 0 rate it Strong Buy, 0 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from VTGN next year?
For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$1.48, with estimates from -$1.50 to -$1.45 from 2 analysts. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$1.54, with estimates from -$1.54 to -$1.54 from 1 analyst.
What revenue do analysts expect from VistaGen Therapeutics next year?
For the fiscal year ending Mar 31, 2027, the consensus revenue estimate is $1.70M, with estimates from $1.50M to $1.90M.
How many analysts cover VTGN?
4 analysts rate VistaGen Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Mar 31, 2027.
VTGN pages: Overview, Earnings, Forecast, Financials, Competitors